U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 81 - 90 of 175 results

Status:
Possibly Marketed Outside US
Source:
NCT04677712: Phase 4 Interventional Completed Edematous Fibrosclerotic Panniculopathy (EFP)
(2020)
Source URL:

Class:
PROTEIN

Conditions:

Status:
US Approved OTC
Source:
21 CFR 349.12(a)(3) ophthalmic:demulcents hydroxypropyl methycellulose
Source URL:
First approved in 1999
Source:
Allercaine with Bittran II by Tomlyn Products, a Division of Vetoquinol USA, Inc.
Source URL:

Class:
POLYMER

Status:
Possibly Marketed Outside US
Source:
Omnivex by Sterling Knight Pharmaceuticals LLC
(2018)
Source URL:
First approved in 1999

Class:
POLYMER